NCT00774046View on ClinicalTrials.gov

High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

December 31, 2002

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Myelodysplastic SyndromeAcute Myeloid Leukemia
Interventions
DRUG

Ara-C

"Induction: 3000mg/m2 IV infusion for day 1 and day 5~Mobilization: within 2 weeks of end of induction therapy - 2000mg/m2 as 2 hour IV infusion once every 12 hours for 3 days (6 doses total)"

DRUG

Mitoxantrone

Induction: 30mg/m2 after the end of HiDAC day 1 and day 5

DRUG

Etoposide

Mobilization: 30mg/kg over 6 doses given once every 12 hours for 3 days

Trial Locations (1)

60637

The University of Chicago, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER

NCT00774046 - High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML | Biotech Hunter | Biotech Hunter